{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:38:03Z","timestamp":1793741883210,"version":"4.6.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874120"],"award-info":[{"award-number":["81874120"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wuhan Science and Technology Bureau","award":["2017060201010170"],"award-info":[{"award-number":["2017060201010170"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) is a common leukemia subtype and has a poor prognosis. The risk of AML is highly related to age. In the context of population aging, a comprehensive report presenting epidemiological trends of AML is evaluable for policy-marker to allocate healthy resources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was based on the Global Burden of Disease 2017 database. We analyzed the change trends of incidence rate, death rate, and disability-adjusted life year (DALY) rate by calculating the corresponding estimated annual percentage change (EAPC) values. Besides, we investigated the influence of social development degree on AML\u2019s epidemiological trends and potential risk factors for AML-related mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 1990 to 2017, the incidence of AML gradually increased in the globe. Males and elder people had a higher possibility to develop AML. Developed countries tended to have higher age-standardized incidence rate and death rate than developing regions. Smoking, high body mass index, occupational exposure to benzene, and formaldehyde were the main risk factors for AML-related mortality. Notably, the contribution ratio of exposure to carcinogens was significantly increased in the low social-demographic index (SDI) region than in the high SDI region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Generally, the burden of AML became heavier during the past 28 years which might need more health resources to resolve this population aging-associated problem. In the present stage, developed countries with high SDI had the most AML incidences and deaths. At the same time, developing countries with middle- or low-middle SDI also need to take actions to relieve rapidly increased AML burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-020-00908-z","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T08:05:46Z","timestamp":1591603546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":226,"title":["The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017"],"prefix":"10.1186","volume":"13","author":[{"given":"Ming","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2499-1032","authenticated-orcid":false,"given":"Kongming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"908_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441.","journal-title":"Blood Cancer J"},{"key":"908_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"908_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"key":"908_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2009.12.001","volume":"20","author":"SW Lane","year":"2010","unstructured":"Lane SW, Gilliland DG. Leukemia stem cells. Semin Cancer Biol. 2010;20:71\u20136.","journal-title":"Semin Cancer Biol"},{"key":"908_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593\u2013606.","journal-title":"Lancet."},{"key":"908_CR6","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","volume":"35","author":"L Bullinger","year":"2017","unstructured":"Bullinger L, D\u00f6hner K, D\u00f6hner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017;35:934\u201346.","journal-title":"J Clin Oncol"},{"key":"908_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, G\u00f6nen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079\u201389.","journal-title":"N Engl J Med"},{"key":"908_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-019-0127-z","volume":"8","author":"P Niparuck","year":"2019","unstructured":"Niparuck P, Limsuwanachot N, Pukiat S, Chantrathammachart P, Rerkamnuaychoke B, Magmuang S, et al. Cytogenetics and FLT3-ITD mutation predict clinical outcomes in nontransplant patients with acute myeloid leukemia. Exp Hematol Oncol. 2019;8:3.","journal-title":"Exp Hematol Oncol"},{"key":"908_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-018-0566-8","volume":"11","author":"H Wei","year":"2018","unstructured":"Wei H, Wang Y, Zhou C, Lin D, Liu B, Liu K, et al. Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and eastern Asian population. J Hematol Oncol. 2018;11:18.","journal-title":"J Hematol Oncol"},{"key":"908_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-018-0675-4","volume":"11","author":"M Wu","year":"2018","unstructured":"Wu M, Li C, Zhu X. FLT3 inhibitors in acute myeloid leukemia. J Hematol Oncol. 2018;11:133.","journal-title":"J Hematol Oncol"},{"key":"908_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40364-019-0178-7","volume":"7","author":"D Liu","year":"2019","unstructured":"Liu D. Cancer biomarkers for targeted therapy. Biomark Res. 2019;7:25.","journal-title":"Biomark Res"},{"key":"908_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40164-019-0158-5","volume":"9","author":"J Yu","year":"2020","unstructured":"Yu J, Li Y, Li T, Li Y, Xing H, Sun H, et al. Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia. Exp Hematol Oncol. 2020;9:2.","journal-title":"Exp Hematol Oncol"},{"key":"908_CR13","first-page":"317","volume":"113","author":"M Heuser","year":"2016","unstructured":"Heuser M, Thol F, Ganser A. Clonal hematopoiesis of indeterminate potential. Dtsch Arztebl Int. 2016;113:317\u201322.","journal-title":"Dtsch Arztebl Int"},{"key":"908_CR14","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-17-3044","volume":"24","author":"CJ Gibson","year":"2018","unstructured":"Gibson CJ, Steensma DP. New insights from studies of clonal hematopoiesis. Clin Cancer Res. 2018;24:4633\u201342.","journal-title":"Clin Cancer Res"},{"key":"908_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc.2017.60","volume":"17","author":"ME McNerney","year":"2017","unstructured":"McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017;17:513\u201327.","journal-title":"Nat Rev Cancer"},{"key":"908_CR16","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.mayocp.2018.04.002","volume":"93","author":"DP Steensma","year":"2018","unstructured":"Steensma DP. Clinical implications of clonal hematopoiesis. Mayo Clin Proc. 2018;93:1122\u201330.","journal-title":"Mayo Clin Proc"},{"key":"908_CR17","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"TN Wong","year":"2015","unstructured":"Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518:552\u20135.","journal-title":"Nature."},{"key":"908_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","volume":"127","author":"H Dombret","year":"2016","unstructured":"Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127:53\u201361.","journal-title":"Blood."},{"key":"908_CR19","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","volume":"125","author":"G Ossenkoppele","year":"2015","unstructured":"Ossenkoppele G, L\u00f6wenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125:767\u201374.","journal-title":"Blood."},{"key":"908_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-019-0774-x","volume":"12","author":"C Lai","year":"2019","unstructured":"Lai C, Doucette K, Norsworthy K. Recent drug approvals for acute myeloid leukemia. J Hematol Oncol. 2019;12:100.","journal-title":"J Hematol Oncol"},{"key":"908_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40364-018-0146-7","volume":"6","author":"R Gu","year":"2018","unstructured":"Gu R, Yang X, Wei H. Molecular landscape and targeted therapy of acute myeloid leukemia. Biomark Res. 2018;6:32.","journal-title":"Biomark Res."},{"key":"908_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40364-019-0170-2","volume":"7","author":"J Zhao","year":"2019","unstructured":"Zhao J, Song Y, Liu D. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomark Res. 2019;7:19.","journal-title":"Biomark Res"},{"key":"908_CR23","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","volume":"19","author":"J Cortes","year":"2018","unstructured":"Cortes J, Perl AE, D\u00f6hner H, Kantarjian H, Martinelli G, Kovacsovics T, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19:889\u2013903.","journal-title":"Lancet Oncol"},{"key":"908_CR24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454\u201364.","journal-title":"N Engl J Med"},{"key":"908_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-017-0543-7","volume":"11","author":"X Yang","year":"2018","unstructured":"Yang X, Wang J. Precision therapy for acute myeloid leukemia. J Hematol Oncol. 2018;11:3.","journal-title":"J Hematol Oncol"},{"key":"908_CR26","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/annonc\/mdw015","volume":"27","author":"TM Kadia","year":"2016","unstructured":"Kadia TM, Ravandi F, Cortes J, Kantarjian H. New drugs in acute myeloid leukemia. Ann Oncol. 2016;27:770\u20138.","journal-title":"Ann Oncol"},{"key":"908_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000486228","volume":"139","author":"X Song","year":"2018","unstructured":"Song X, Peng Y, Wang X, Chen Y, Jin L, Yang T, et al. Incidence, survival, and risk factors for adults with acute myeloid leukemia not otherwise specified and acute myeloid leukemia with recurrent genetic abnormalities: analysis of the surveillance, epidemiology, and end results (SEER) database, 2001\u20132013. Acta Haematol. 2018;139:115\u201327.","journal-title":"Acta Haematol"},{"key":"908_CR28","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/risa.12956","volume":"38","author":"S Fiebelkorn","year":"2018","unstructured":"Fiebelkorn S, Meredith C. Estimation of the leukemia risk in human populations exposed to benzene from tobacco smoke using epidemiological data. Risk Anal. 2018;38:1490\u2013501.","journal-title":"Risk Anal"},{"key":"908_CR29","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/ijc.26151","volume":"130","author":"R Varadarajan","year":"2012","unstructured":"Varadarajan R, Licht AS, Hyland AJ, Ford LA, Sait SN, Block AW, et al. Smoking adversely affects survival in acute myeloid leukemia patients. Int J Cancer. 2012;130:1451\u20138.","journal-title":"Int J Cancer"},{"key":"908_CR30","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1002\/cncr.30183","volume":"122","author":"LJ Costa","year":"2016","unstructured":"Costa LJ, Brill IK, Brown EE. Impact of marital status, insurance status, income, and race\/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States. Cancer. 2016;122:3183\u201390.","journal-title":"Cancer."},{"key":"908_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-019-0799-1","volume":"12","author":"L Zhou","year":"2019","unstructured":"Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, et al. Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 global burden of disease study. J Hematol Oncol. 2019;12:107.","journal-title":"J Hematol Oncol"},{"key":"908_CR32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13045-019-0828-0","volume":"12","author":"N Li","year":"2019","unstructured":"Li N, Deng Y, Zhou L, Tian T, Yang S, Wu Y, et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the global burden of disease study 2017. J Hematol Oncol. 2019;12:140.","journal-title":"J Hematol Oncol"},{"key":"908_CR33","doi-asserted-by":"crossref","unstructured":"Zjablovskaja P, Florian MC. Acute myeloid leukemia: aging and epigenetics. Cancers (Basel). 2019;12:\u2013103.","DOI":"10.3390\/cancers12010103"},{"key":"908_CR34","doi-asserted-by":"publisher","first-page":"306fs38","DOI":"10.1126\/scitranslmed.aac4428","volume":"7","author":"T McKerrell","year":"2015","unstructured":"McKerrell T, Vassiliou GS. Aging as a driver of leukemogenesis. Sci Transl Med. 2015;7:306fs38.","journal-title":"Sci Transl Med"},{"key":"908_CR35","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488\u201398.","journal-title":"N Engl J Med"},{"key":"908_CR36","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, K\u00e4hler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477\u201387.","journal-title":"N Engl J Med"},{"key":"908_CR37","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/cncr.22233","volume":"107","author":"B Deschler","year":"2006","unstructured":"Deschler B, L\u00fcbbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107:2099\u2013107.","journal-title":"Cancer."},{"key":"908_CR38","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/10428194.2017.1330956","volume":"59","author":"JA Webster","year":"2018","unstructured":"Webster JA, Pratz KW. Acute myeloid leukemia in the elderly: therapeutic options and choice. Leuk Lymphoma. 2018;59:274\u201387.","journal-title":"Leuk Lymphoma"},{"key":"908_CR39","doi-asserted-by":"publisher","first-page":"62666","DOI":"10.18632\/oncotarget.16989","volume":"8","author":"Z Zheng","year":"2017","unstructured":"Zheng Z, Zhu Y, Li X, Hu W, Jiang J. Impact of marital status during diagnosis on cancer-caused specific survival in acute myeloid leukemia patients: a case-control and population-based study. Oncotarget. 2017;8:62666\u201380.","journal-title":"Oncotarget."},{"key":"908_CR40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/COC.0b013e3181dea934","volume":"34","author":"MM Byrne","year":"2011","unstructured":"Byrne MM, Halman LJ, Koniaris LG, Cassileth PA, Rosenblatt JD, Cheung MC. Effects of poverty and race on outcomes in acute myeloid leukemia. Am J Clin Oncol. 2011;34:297\u2013304.","journal-title":"Am J Clin Oncol"},{"key":"908_CR41","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1158\/1055-9965.EPI-14-0963","volume":"24","author":"MI Patel","year":"2015","unstructured":"Patel MI, Ma Y, Mitchell B, Rhoads KF. How do differences in treatment impact racial and ethnic disparities in acute myeloid leukemia? Cancer Epidemiol Biomark Prev. 2015;24:344\u20139.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"908_CR42","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1002\/cncr.27442","volume":"118","author":"SS Strom","year":"2012","unstructured":"Strom SS, Oum R, Elhor Gbito KY, Garcia-Manero G, Yamamura Y. De novo acute myeloid leukemia risk factors: a Texas case-control study. Cancer. 2012;118:4589\u201396.","journal-title":"Cancer."},{"key":"908_CR43","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.leukres.2008.10.009","volume":"33","author":"J Bj\u00f6rk","year":"2009","unstructured":"Bj\u00f6rk J, Johansson B, Broberg K, Albin M. Smoking as a risk factor for myelodysplastic syndromes and acute myeloid leukemia and its relation to cytogenetic findings: a case-control study. Leuk Res. 2009;33:788\u201391.","journal-title":"Leuk Res"},{"key":"908_CR44","doi-asserted-by":"publisher","first-page":"E125","DOI":"10.1002\/ajh.23744","volume":"89","author":"S Fircanis","year":"2014","unstructured":"Fircanis S, Merriam P, Khan N, Castillo JJ. The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies. Am J Hematol. 2014;89:E125\u201332.","journal-title":"Am J Hematol"},{"key":"908_CR45","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/sj.leu.2404698","volume":"21","author":"MA Lichtman","year":"2007","unstructured":"Lichtman MA. Cigarette smoking, cytogenetic abnormalities, and acute myelogenous leukemia. Leukemia. 2007;21:1137\u201340.","journal-title":"Leukemia."},{"key":"908_CR46","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/annonc\/mdf269","volume":"13","author":"Y Chelghoum","year":"2002","unstructured":"Chelghoum Y, Dana\u00efla C, Belhabri A, Charrin C, Le QH, Michallet M, et al. Influence of cigarette smoking on the presentation and course of acute myeloid leukemia. Ann Oncol. 2002;13:1621\u20137.","journal-title":"Ann Oncol"},{"key":"908_CR47","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.canep.2015.12.005","volume":"40","author":"JN Poynter","year":"2016","unstructured":"Poynter JN, Richardson M, Blair CK, Roesler MA, Hirsch BA, Nguyen P, et al. Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes. Cancer Epidemiol. 2016;40:134\u201340.","journal-title":"Cancer Epidemiol"},{"key":"908_CR48","doi-asserted-by":"publisher","first-page":"17998","DOI":"10.1038\/s41598-017-18278-x","volume":"7","author":"S Li","year":"2017","unstructured":"Li S, Chen L, Jin W, Ma X, Ma Y, Dong F, et al. Influence of body mass index on incidence and prognosis of acute myeloid leukemia and acute promyelocytic leukemia: a meta-analysis. Sci Rep. 2017;7:17998.","journal-title":"Sci Rep"},{"key":"908_CR49","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ajh.20934","volume":"82","author":"EA Natelson","year":"2007","unstructured":"Natelson EA. Benzene-induced acute myeloid leukemia: a clinician\u2019s perspective. Am J Hematol. 2007;82:826\u201330.","journal-title":"Am J Hematol"},{"key":"908_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ijc.30420","volume":"140","author":"JN Poynter","year":"2017","unstructured":"Poynter JN, Richardson M, Roesler M, Blair CK, Hirsch B, Nguyen P, et al. Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study. Int J Cancer. 2017;140:23\u201333.","journal-title":"Int J Cancer"},{"key":"908_CR51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1476-069X-9-31","volume":"9","author":"A Khalade","year":"2010","unstructured":"Khalade A, Jaakkola MS, Pukkala E, Jaakkola JJ. Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. Environ Health. 2010;9:31.","journal-title":"Environ Health"},{"key":"908_CR52","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/carcin\/bgu229","volume":"36","author":"Q Lan","year":"2015","unstructured":"Lan Q, Smith MT, Tang X, Guo W, Vermeulen R, Ji Z, et al. Chromosome-wide aneuploidy study of cultured circulating myeloid progenitor cells from workers occupationally exposed to formaldehyde. Carcinogenesis. 2015;36:160\u20137.","journal-title":"Carcinogenesis."},{"key":"908_CR53","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1080\/10408444.2017.1301878","volume":"47","author":"KA Mundt","year":"2017","unstructured":"Mundt KA, Gallagher AE, Dell LD, Natelson EA, Boffetta P, Gentry PR. Does occupational exposure to formaldehyde cause hematotoxicity and leukemia-specific chromosome changes in cultured myeloid progenitor cells? Crit Rev Toxicol. 2017;47:592\u2013602.","journal-title":"Crit Rev Toxicol"},{"key":"908_CR54","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood."},{"key":"908_CR55","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/cancers10110429","volume":"10","author":"M Luppi","year":"2018","unstructured":"Luppi M, Fabbiano F, Visani G, Martinelli G, Venditti A. Novel agents for acute myeloid leukemia. Cancers (Basel). 2018;10:429.","journal-title":"Cancers (Basel)"},{"key":"908_CR56","doi-asserted-by":"publisher","first-page":"204062071986064","DOI":"10.1177\/2040620719860645","volume":"10","author":"ES Winer","year":"2019","unstructured":"Winer ES, Stone RM. Novel therapy in acute myeloid leukemia (AML): moving toward targeted approaches. Ther Adv Hematol. 2019;10:2040620719860645.","journal-title":"Ther Adv Hematol"},{"key":"908_CR57","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/leu.2015.214","volume":"30","author":"C Krupka","year":"2016","unstructured":"Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, K\u00f6hnke T, et al. Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia. 2016;30:484\u201391.","journal-title":"Leukemia."},{"key":"908_CR58","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","volume":"23","author":"QS Wang","year":"2015","unstructured":"Wang QS, Wang Y, Lv HY, Han QW, Fan H, Guo B, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 2015;23:184\u201391.","journal-title":"Mol Ther"},{"key":"908_CR59","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","volume":"122","author":"A Mardiros","year":"2013","unstructured":"Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122:3138\u201348.","journal-title":"Blood."},{"key":"908_CR60","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase ii study. Cancer Discov. 2019;9:370\u201383.","journal-title":"Cancer Discov"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00908-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-020-00908-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00908-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T19:43:31Z","timestamp":1623095011000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-00908-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["908"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-00908-z","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"6 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}